Search results for "Phoma"

showing 10 items of 716 documents

Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study

2015

Background: Incidence rates of lymphoma are usually higher in men than in women, and oestrogens may protect against lymphoma. Methods: We evaluated occupational exposure to endocrine disrupting chemicals (EDCs) among 2457 controls and 2178 incident lymphoma cases and subtypes from the European Epilymph study. Results: Over 30 years of exposure to EDCs compared to no exposure was associated with a 24% increased risk of mature B-cell neoplasms (P-trend=0.02). Associations were observed among men, but not women. Conclusions: Prolonged occupational exposure to endocrine disruptors seems to be moderately associated with some lymphoma subtypes. © 2015 Cancer Research UK. All rights reserved.

OncologyMaleendocrine systemCancer Researchmedicine.medical_specialtyanimal structuresLymphomaEpidemiologyJob-exposure matrixchemicalsEndocrine Disruptors03 medical and health sciences0302 clinical medicineSex FactorsSex factorsRisk FactorsInternal medicinehemic and lymphatic diseasesOccupational ExposuremedicineOccupational exposure - endocrine disrupting chemicals (EDCs) - lymphoma riskEndocrine systemHumansurogenital systembusiness.industryIncidence (epidemiology)IncidenceCase-control studynutritional and metabolic diseasespesticidesmedicine.disease030210 environmental & occupational health3. Good healthLymphomaEuropeOccupational DiseasessolventsOncologyMulticenter study030220 oncology & carcinogenesisCase-Control StudiesImmunologyleukaemiaalkylphenolsFemaleOccupational exposurebusinesshormones hormone substitutes and hormone antagonists
researchProduct

The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy includi…

2015

Part of this study has been reported as an oral presentation at the EHA Meeting in Vienna 2015.

OncologyMalemedicine.medical_treatmentarray-based comparative genomic hybridization (aCGH)Intensive chemotherapyKaplan-Meier EstimateBioinformatics0302 clinical medicinerituximabAntineoplastic Combined Chemotherapy ProtocolsYoung adultComparative Genomic HybridizationGenomeArray-based comparative genomic hybridizationBurkitt lymphomaHigh-Throughput Nucleotide SequencingHematologyMiddle AgedPrognosisBurkitt Lymphomahumanities3. Good healthTreatment Outcome030220 oncology & carcinogenesisoutcomeRituximabFemaleRituximabmedicine.drugAdultmedicine.medical_specialtyAdolescenteducationBiologyNext-generation sequencing outcome03 medical and health sciencesYoung AdultInternal medicinemedicineHumansIn patientAgedChromosome AberrationsChemotherapymedicine.diseaseGNA13Lymphomastomatognathic diseasesnext-generation sequencing030215 immunologyComparative genomic hybridization
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Childhood cancer incidence and survival in Spain

2010

Abstract Background: This article affords an overview of the patterns and time trends of childhood cancer incidence (1983–2002) and survival (1991–2002) in Spain. Patients and methods: A population-based study was conducted, including 5936 cases for incidence and 3257 for survival analyses. Differences in incidence were tested with the standardised incidence ratio. Trends were analysed for all tumours, and for all malignant, haematological, central nervous system (CNS) (all and only malignant) and other solid tumours. Incidence trends were analysed using Poisson and Bayesian joinpoint models. Observed, relative and age-adjusted survival rates were calculated, and trends were tested using th…

OncologyMaletrendsmedicine.medical_specialtyPathologyAdolescentPopulationChildhood cancersurvivalInternal medicineNeoplasmsEpidemiologymedicineHumanschildhood cancerRegistrieseducationChildSurvival rateeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceAge FactorsInfant NewbornInfantHematologymedicine.diseaseLymphomaLog-rank testSurvival RateLeukemiaOncologycancer registriesSpainChild PreschoolincidenceFemalebusiness
researchProduct

Rituximab in the treatment of non-Hodgkin’s lymphoma

2008

Beate Hauptrock, Georg HessHematology/Oncology, Johannes Gutenberg-University, Mainz, GermanyAbstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL).  Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cel…

OncologyMedicine (General)medicine.medical_specialtybusiness.industryFollicular lymphomaCHOPmedicine.diseaseLymphomaNon-Hodgkin's lymphomaR5-920immune system diseasesChemoimmunotherapyhemic and lymphatic diseasesInternal medicineMonoclonalImmunologymedicineMantle cell lymphomaRituximabbusinessmedicine.drugBiologics: Targets & Therapy
researchProduct

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature res…

2014

Summary Salvage therapy followed by high-dose therapy (HDT) remains a mainstay for patients with relapsed lymphoma, however no optimal regimen has been defined. Here we report on the results of R-DexaBEAM (rituximab, dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by HDT. Patients aged 18–65 years, Eastern Cooperative Oncology Group performance score 0–2, with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) were eligible. R-Dexa-BEAM was given for two cycles followed by stem cell mobilization and HDT. Primary endpoint of the trial was progression-free-survival (PFS). One hundred and three patients were included: aggressive NHL (aNHL): diffuse large B-cell lymphom…

OncologyMelphalanAdultMalemedicine.medical_specialtyLymphoma B-CellFollicular lymphomaSalvage therapyKaplan-Meier EstimateDexamethasoneDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedYoung Adultimmune system diseasesRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAutologous transplantationHumansProspective StudiesMelphalanEtoposideAgedEtoposideSalvage TherapyDose-Response Relationship Drugbusiness.industryPatient SelectionRemission InductionCytarabineHematologyMiddle Agedmedicine.diseaseCarmustineHematopoietic Stem Cell MobilizationLymphomaSurgeryMantle cell lymphomaRituximabFemalebusinessRituximabmedicine.drugBritish journal of haematology
researchProduct

Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, eto…

2012

6543 Background: High-dose therapy and autologous stem cell transplantation (ASCT) in patients (pts) with aggressive B-NHL failing from immunochemotherapy including rituximab show poor outcome with 3y PFS of 39% (Gisselbrecht et al. JCO 2010). Combining BEAM with 90yttrium ibritumomab tiuxetan is a promising option to enhance the efficacy of the high-dose regimen. Methods: Pts without disease progression during salvage therapy of relapsed or refractory CD20+ aggressive B-NHL were included in this prospective, multicenter, phase I/II trial. Primary endpoint was the maximum tolerated dose of 90Yttrium ibritumomab tiuxetan given as close as possible to ASCT defined as <2 pts with dose limi…

OncologyMelphalanCancer Researchmedicine.medical_specialtybusiness.industryIbritumomab tiuxetanAutologous stem-cell transplantationOncologyRefractoryInternal medicinemedicineB-Cell Non-Hodgkin LymphomaCytarabineRituximabbusinessEtoposidemedicine.drugJournal of Clinical Oncology
researchProduct

The role of stem cell transplantation in follicular lymphoma.

2017

With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly used in patients with a highrisk profile, e.g. failure of response, early or multiply relapse and/or signs of transformation. The ideal place for allogeneic transplantation is even harder to define, …

Oncologymedicine.medical_specialtyAllogeneic transplantationSide effectClinical BiochemistryFollicular lymphomaTransplantation Autologous03 medical and health sciences0302 clinical medicineInternal medicinemedicineAutologous transplantationHumansIn patientPrecision MedicineLymphoma Follicularbusiness.industryHematopoietic Stem Cell Transplantationmedicine.diseaseTransplantationOncology030220 oncology & carcinogenesisRituximabStem cellbusinessRituximab030215 immunologymedicine.drugBest practiceresearch. Clinical haematology
researchProduct

Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group

2021

Haematologica : journal of the European Hematology Association 106(5), 1390-1400 (2021). doi:10.3324/haematol.2019.244780

Oncologymedicine.medical_specialtyArticle03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansCumulative incidence030304 developmental biology0303 health sciencesChildhood Cancer RegistryUnivariate analysisbusiness.industryIncidenceLymphoma Non-HodgkinMyelodysplastic syndromesIncidence (epidemiology)Lymphoblastic lymphomaMyeloid leukemiaNeoplasms Second PrimaryHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLymphoma030220 oncology & carcinogenesisFemaleCranial Irradiationbusiness
researchProduct

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cel…

2011

Abstract Abstract 3089 Introduction: High-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) demonstrated high efficacy in the treatment of newly-diagnosed primary CNS lymphoma (PCNSL) in eligible patients (pts). Prognosis of PCNSL is associated with several clinical and histopathological risk factors (RF). Early complete response (CR) during chemotherapy (CHT) was recently reported to be an additional independent prognostic factor in pts undergoing polychemotherapy without HDT+ASCT. In this analysis, we examined the extent to which known RF determined survival in pts who were treated with HDT-ASCT. We additionally investigated the impact of HDT-ASCT specific factors (e…

Oncologymedicine.medical_specialtyChemotherapyPerformance statusbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologyPrimary central nervous system lymphomaCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationInternal medicineMedicineStem cellbusinessmedicine.drugBlood
researchProduct